The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
In Vitro and In Vivo Antibacterial Activities of a Novel Glycylcycline, the 9- t -Butylglycylamido Derivative of Minocycline (GAR-936)
Open accessAbstract
The 9- t -butylglycylamido derivative of minocycline (TBG-MINO) is a recently synthesized member of a novel group of antibiotics, the glycylcyclines. This new derivative, like the first glycylcyclines, the N , N -dimethylglycylamido derivative of minocycline and 6-demethyl-6-deoxytetracycline, possesses activity against bacterial isolates containing the two major determinants responsible for tetracycline resistance: ribosomal protection and active efflux. The in vitro activities of TBG-MINO and the comparative agents were evaluated against strains with characterized tetracycline resistance as well as a spectrum of recent clinical aerobic and anaerobic gram-positive and gram-negative bacteria. TBG-MINO, with an MIC range of 0.25 to 0.5 μg/ml, showed good activity against strains expressing tet (M) (ribosomal protection), tet (A), tet (B), tet (C), tet (D), and tet (K) (efflux resistance determinants). TBG-MINO exhibited similar activity against methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant streptococci, and vancomycin-resistant enterococci (MICs at which 90% of strains are inhibited, ≤0.5 μg/ml). TBG-MINO exhibited activity against a wide diversity of gram-negative aerobic and anaerobic bacteria, most of which were less susceptible to tetracycline and minocycline. The in vivo protective effects of TBG-MINO were examined against acute lethal infections in mice caused by Escherichia coli , S. aureus , and Streptococcus pneumoniae isolates. TBG-MINO, administered intravenously, demonstrated efficacy against infections caused by S. aureus including MRSA strains and strains containing tet (K) or tet (M) resistance determinants (median effective doses [ED 50 s], 0.79 to 2.3 mg/kg of body weight). TBG-MINO demonstrated efficacy against infections caused by tetracycline-sensitive E. coli strains as well as E. coli strains containing either tet (M) or the efflux determinant tet (A), tet (B), or tet (C) (ED 50 s, 1.5 to 3.5 mg/kg). Overall, TBG-MINO shows antibacterial activity against a wide spectrum of gram-positive and gram-negative aerobic and anaerobic bacteria including strains resistant to other chemotherapeutic agents. The in vivo protective effects, especially against infections caused by resistant bacteria, corresponded with the in vitro activity of TBG-MINO.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
Principles and Practice of Infectious Diseases.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-818_5 · Cited by 12,025
Lewis, J. A., & Finney, D. (1972) · Applied Statistics · doi:10.2307/2346498 · Cited by 2,665
The life and times of the Enterococcus
Murray, B. E. (1990) · Clinical Microbiology Reviews · doi:10.1128/cmr.3.1.46 · Cited by 1,908
Wadsworth anaerobic bacteriology manual
Sutter, V. L., Citron, D. M., & Finegold, S. M. (1980) · Medical Entomology and Zoology · Cited by 1,388
VANCOMYCIN-RESISTANT ENTEROCOCCI
Uttley, A. C., Collins, C. H., Naidoo, J., & George, R. C. (1988) · The Lancet · doi:10.1016/s0140-6736(88)91037-9 · Cited by 1,226
Identification of Enterococcus species isolated from human infections by a conventional test scheme
Facklam, R. R., & Collins, M. D. (1989) · Journal of Clinical Microbiology · doi:10.1128/jcm.27.4.731-734.1989 · Cited by 791
Mulligan, M. E., Murray-Leisure, K. A., Ribner, B. S., Standiford, H. C., John, J. F., Korvick, J. A., Kauffman, C. A., & Yu, V. L. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90063-u · Cited by 641
Bacterial resistance to tetracycline: mechanisms, transfer, and clinical significance
Speer, B. S., Shoemaker, N. B., & Salyers, A. A. (1992) · Clinical Microbiology Reviews · doi:10.1128/cmr.5.4.387 · Cited by 517
Cited by
Chopra, I., & Roberts, M. (2001) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.65.2.232-260.2001 · Cited by 4,517
Acinetobacter baumannii : Emergence of a Successful Pathogen
Peleg, A. Y., Seifert, H., & Paterson, D. L. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-07 · Cited by 3,316
Antibiotics and Bacterial Resistance in the 21st Century
Fair, R. J., & Tor, Y. (2014) · Perspectives in Medicinal Chemistry · doi:10.4137/pmc.s14459 · Cited by 1,955
The Challenge of Efflux-Mediated Antibiotic Resistance in Gram-Negative Bacteria
Li, X.-Z., Plésiat, P., & Nikaido, H. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00117-14 · Cited by 1,614
Tamma, P. D., Heil, E. L., Justo, J. A., Mathers, A. J., Satlin, M. J., & Bonomo, R. A. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae403 · Cited by 1,191
Pharmacokinetic issues for antibiotics in the critically ill patient
Roberts, J. A., & Lipman, J. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181961bff · Cited by 862
Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad428 · Cited by 740
Tetracycline Antibiotics and Resistance
Grossman, T. H. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025387 · Cited by 725
The role of antibiotics and antibiotic resistance in nature
Aminov, R. I. (2009) · Environmental Microbiology · doi:10.1111/j.1462-2920.2009.01972.x · Cited by 687
Ji, H., Li, X., & Zhang, H. (2009) · EMBO reports · doi:10.1038/embor.2009.12 · Cited by 636
Tetracycline antibiotics and resistance mechanisms
Nguyen, F., Starosta, A. L., Arenz, S., Sohmen, D., Dönhöfer, A., & Wilson, D. N. (2014) · Biological Chemistry · doi:10.1515/hsz-2013-0292 · Cited by 528
Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1013 · Cited by 519
Efflux-Mediated Antibiotic Resistance in Acinetobacter spp
Coyne, S., Courvalin, P., & Périchon, B. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01388-10 · Cited by 505
Current control and treatment of multidrug-resistant Acinetobacter baumannii infections
Karageorgopoulos, D. E., & Falagas, M. E. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(08)70279-2 · Cited by 446
Ellis‐Grosse, E. J., Babinchak, T., Dartois, N., Rose, G., Loh, E., & Groups, T. 3. A. 3. C. S. (2005) · Clinical Infectious Diseases · doi:10.1086/431675 · Cited by 414
Babinchak, T., Ellis‐Grosse, E., Dartois, N., Rose, G. M., Loh, E., & Groups, T. 3. A. 3. S. (2005) · Clinical Infectious Diseases · doi:10.1086/431676 · Cited by 381
Damier-Piolle, L., Magnet, S., Brémont, S., Lambert, T., & Courvalin, P. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00732-07 · Cited by 357
Pharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy Subjects
Muralidharan, G., Micalizzi, M., Speth, J., Raible, D., & Troy, S. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.1.220-229.2005 · Cited by 333
Community-acquired methicillin-resistant Staphylococcus aureus
Elston, D. M. (2007) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.04.018 · Cited by 308
The Glycylcyclines: A Comparative Review with the Tetracyclines
Zhanel, G. G., Homenuik, K., Nichol, K., Noreddin, A., Vercaigne, L., Embil, J., Gin, A., Karlowsky, J. A., & Hoban, D. J. (2004) · Drugs · doi:10.2165/00003495-200464010-00005 · Cited by 306
Pankey, G. A. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki248 · Cited by 301
Maynard, C., Fairbrother, J. M., Bekal, S., Sanschagrin, F., Levesque, R. C., Brousseau, R., Masson, L., Larivière, S., & Harel, J. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.10.3214-3221.2003 · Cited by 299
Tigecycline: A Critical Analysis
Stein, G. E., & Craig, W. A. (2006) · Clinical Infectious Diseases · doi:10.1086/505494 · Cited by 298
Efflux-Mediated Resistance to Tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1
Dean, C. R., Visalli, M. A., Projan, S. J., Sum, P.-E., & Bradford, P. A. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.3.972-978.2003 · Cited by 286
Self-citationTigecycline: what is it, and where should it be used?
Livermore, D. M. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki291 · Cited by 261
Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii
Peleg, A. Y., Adams, J., & Paterson, D. L. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01198-06 · Cited by 257
Functional, biophysical, and structural bases for antibacterial activity of tigecycline
Olson, M. W., Ruzin, A., Feyfant, E., Rush, T. S., O'Connell, J., & Bradford, P. A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01499-05 · Cited by 207
Visalli, M. A., Murphy, E., Projan, S. J., & Bradford, P. A. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.2.665-669.2003 · Cited by 165
New developments in tetracycline antibiotics: Glycylcyclines and tetracycline efflux pump inhibitors
Chopra, I. (2002) · Drug Resistance Updates · doi:10.1016/s1368-7646(02)00051-1 · Cited by 143
Minocycline inhibits angiogenesis in vitro through the translational suppression of HIF-1α
Jung, H.-J., Seo, I., Jha, B. K., Suh, S.-I., Suh, M.-H., & Baek, W.-K. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2013.12.023 · Cited by 27
Metadata
- Authors
- Petersen, P. J., Jacobus, N. V., Weiss, W. J., Sum, P. E., & Testa, R. T.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1999-04
- Volume
- 43
- Issue
- 4
- Pages
- 738-744
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2156737450
- Cited by
- 415
- References
- 30
- FWCI
- 8.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.